ArticleBreast cancer : basic and clinical research2012

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

Eugene R Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.